New Delhi: The Mylan Pharmaceuticals has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza (TLE400).
Avonza is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg, recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS.
Commenting on the launch, Mylan President Rajiv Malik mentioned, “Developing Avonza and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high-quality ARVs. Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs. What’s more, Mylan is the first to offer this combination in India, making it another example of the innovative spirit that runs throughout our company to adapt our medicines, accelerate access and improve treatment outcomes.”
WHO recommended antiretroviral, Avonza is expected to help in expanding access to HIV-AIDS patients in India at a lower cost.